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Abstract 
Background: Trans‑ferulic (FA) acid exhibits antioxidant effects in vitro. However, the underlying mechanism of trans‑
FA activity in cellular physiology, especially cancer physiology, remains largely unknown. This study investigated the 
cellular physiological effects of trans‑FA on the H1299 human lung cancer cell line.
Methods: The 2,2‑diphenyl‑1‑picrylhydrazyl assay was used to determine free radical scavenging capability. Assess‑
ment of intracellular reactive oxygen species (ROS) was evaluated using oxidized 2ʹ,7ʹ‑dichlorofluorescin diacetate 
and dihydroethidium staining. Trypan blue exclusion, colony formation, and anchorage‑independent growth assays 
were used to determine cellular proliferation. Annexin V staining assay was used to assess cellular apoptosis by flow 
cytometry. Wound healing and Boyden’s well assays were used to detect the migration and invasion of cells. Gelatin 
zymography was used to detect matrix metalloproteinase (MMP‑2 and MMP‑9) activity. Western blotting was used to 
detect expression levels of various signaling pathway proteins.
Results: DPPH assay results indicated that trans‑FA exerted potent antioxidant effects. However, trans‑FA increased 
intracellular ROS levels, including hydrogen peroxide and superoxide anion, in H1299 cells. Trans‑FA treatment inhib‑
ited cellular proliferation and induced moderate apoptotic cell death at the highest concentration used (0.6 mM). 
Furthermore, trans‑FA moderately inhibited the migration of H1299 cells at the concentrations of 0.3 and 0.6 mM and 
attenuated MMP‑2 and MMP‑9 activity. Trans‑FA caused the phosphorylation of β‑catenin, resulting in proteasomal 
degradation of β‑catenin. Conversely, trans‑FA treatment increased the expression of pro‑apoptotic factor Bax and 
decreased the expression of pro‑survival factor survivin.
Conclusion: Various concentrations (0.06–0.6 mM) of trans‑FA exert both anti‑proliferation and anti‑migration effects 
in the human lung cancer cell line H1299.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In 2013, the mortality rates for male and female lung 
cancer patients in the United States were 28 and 26  %, 
respectively [1]. At present, chemotherapy is the primary 
treatment for lung cancer [2–4], with both carboplatin 
and cisplatin commonly used as chemotherapy drugs [5, 
6]. However, the combination of cisplatin or vinblastine 
with irradiation increases the level of unexpected toxicity 
in the body [4]. Pemetrexed (Alimta®), a next-generation 
antifolate drug, is used for treating malignant pleural 
mesothelioma and non-small cell lung cancer (NSCLC) 
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but can induce scleroderma-like induration of the lower 
extremities [7]. It is therefore necessary to develop alter-
native treatment strategies for selective inhibition of lung 
cancer cells growth.
The carcinogenic process may be driven by mutations, 
leading to alterations in phenotypes, genetics, and epige-
netics. The induction of oxidative stress in various cancer 
cells such as human pancreatic and colon adenocarci-
noma cancer cell lines [8] was shown to inhibit expression 
of β-catenin and the matrix metalloproteinases MMP-2 
and MMP-9 in colitis-associated colon carcinoma [9], 
induce Bax expression in urothelial cell carcinoma [10], 
induce apoptosis by blocking the AMPK-mTOR-survivin 
pathway [11], and inhibit the anchorage-independent 
growth (AIG) of transformed cells [12]. Chemopreven-
tive treatment is moderate or non-cytotoxic to normal 
cells, but significantly inhibits cancer cell growth or 
metastasis. Accumulating evidence shows that anti-oxi-
dative compounds isolated from plants exert potentially 
chemopreventive effects. Among these compounds are 
carotenoids, curcumin, and hesperidin [13, 14]. Recently, 
anticancer compounds derived from plants, including 
goniothalamin and feruloyl-l-arabinose, were shown to 
inhibit the growth and metastasis of human lung cancer 
cells [15, 16]. Additionally, moscatilin, isolated from the 
orchid Dendrobrium loddigesii, inhibited metastasis of 
both human breast and lung cancer cells [17, 18].
Ferulic acid (FA) is an aromatic compound, abundant 
in plant cell walls [19, 20]. Both isomers of FA, cis-FA 
and trans-FA, show a potent ability to remove reactive 
oxygen species (ROS) and inhibit lipid peroxidation [20, 
21]. Unlike cis-FA, trans-FA is abundant in plant cells 
and easily isolated from various plants, thus significantly 
reducing the cost of its preparation [22].
Trans-FA ameliorated ionizing radiation-induced 
inflammation and glycerol-induced nephrotoxicity [23, 
24] and modulated fluoride-induced oxidative hepato-
toxicity in male Wistar rats [25]. Water-soluble trans-FA 
sugar esters protected normal rat erythrocytes against 
peroxyl radical 2,2ʹ-azobis-2-amidinopropane dihydro-
chloride (AAPH)-induced oxidative damage [26] and 
exhibited protective capacity against oxidative dam-
age caused by diabetes [27, 28]. Furthermore, trans-FA 
exhibited antiproliferative effects in colon cancer cells 
[29, 30], increased the radiosensitivity of cervical cancer 
cells [31], and exerted protective effects against chemical-
induced DNA strand breaks [32, 33]. However, the effects 
of trans-FA in lung cancer have not been reported to 
date, and its biological mechanism remains unknown.
The study investigated the cellular and physiological 
effects of trans-FA in human lung cancer cells.
Methods
Chemicals
Trans-FA (4-hydroxy-3-methoxycinnamic acid) was 
purchased from Sigma-Aldrich Chemicals (#128708, 
St. Louis, MO, USA). Trans-FA was freshly dissolved in 
0.01 % dimethyl sulfoxide (DMSO) and aliquoted before 
use.
Cell culture
The human non-small cell lung cancer (NSCLC) cell 
line H1299 and lung fibroblast cells HEL-299 were 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA). Cells were maintained in 
DMEM:F-12 medium (1:1 ratio) supplemented with 8 % 
fetal bovine serum, 2 mM glutamine, 100 units/mL peni-
cillin, and 100  µg/mL streptomycin (Gibco BRL, Gaith-
ersburg, MD, USA) at 37 °C in a humidified atmosphere 
of 5 % CO2 [4].
DPPH radical‑scavenging activity assay
The anti-oxidant activities of trans-FA were measured 
based on the scavenging activity of 2,2-diphenyl-1-pic-
rylhydrazyl (DPPH) (#D9132, Sigma-Aldrich) free radical 
[34, 35]. Briefly, vitamin C standards and various trans-
FA concentrations were freshly prepared and diluted in 
methanol. Methanol (as a blank control; 10 µM) or trans-
FA solution was added to 90 µL DPPH solution to yield a 
final trans-FA concentration of 0.15 mg/mL in a 96-well 
microplate. The mixture was incubated at 25 °C and pro-
tected from light. After incubation, solution absorbance 
was measured at 492  nm using a Multiskan Ascent 354 
microplate reader (Thermo Fisher Scientific, Rockford, 
IL, USA). DPPH radical scavenging activity was calcu-
lated as follows:
where A0 and A1 are the absorbances of the control and 
trans-FA solutions, respectively. Each experiment was 
repeated three times and found to be reproducible within 
experimental error margins.
Cell viability and proliferation assay
Briefly, 5 × 104 cells were seeded into wells of a 12-well 
plate and treated with phosphate-buffered saline (PBS) 
(Sigma-Aldrich) as control or concentrations of trans-
FA (0.03–0.6 mM) for 24 or 48 h. After incubation, cell 
viability and proliferation were analyzed by trypan blue 
assay and an automated cell counter (Countess™) accord-
ing to the manufacturer’s instructions (Invitrogen, Carls-
bad, CA, USA).
DPPH radical scavenging activity (%)
= (1− A0/A1) × 100
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Colony formation assay
Fifty cells were seeded into wells of a 6-well plate and, 
after 24 h of incubation, were treated with different con-
centrations of trans-FA (0.03–0.6 mM). After incubation 
for 11  days, cell colonies were glutaraldehyde-fixed and 
stained with crystal violet (0.1 % w/v) for 10 min. Colony 
diameter was determined using Image-Pro v3.0 software 
(Media Cybernetics, Silver Spring, MD, USA).
Anchorage‑independent growth (AIG) assay
The assay procedure was performed as described in our 
previous work, with minor modifications [36]. Briefly, 
1 × 103 cells were mixed with 0.75 % low melting agarose 
(MDBio Inc, Taipei, Taiwan). The mixtures were placed on 
a solidified layer of 1.5 % agarose with medium in a 12-well 
plate. After incubation for 13 days, cells in the upper layer 
were fixed with 1 % glutaraldehyde and stained with 0.1 % 
w/v Giemsa (Merck, Darmstadt, Germany). Colony diam-
eter was determined using Image-Pro v3.0 software.
Cell cycle analysis
Cell cycle distribution was assessed using propidium 
iodide (PI; Sigma-Aldrich) staining described previ-
ously [37]. Briefly, 1  ×  105 cells were treated with PBS 
(as vehicle control) or various trans-FA concentrations 
(0.03–0.6 mM) for 48 h. Next, cells were detached using 
0.05  % trypsin (Biological Industries, Kibbutz Beit Hae-
mek, Israel) for 5 min, harvested, and washed with PBS. 
Cells were then fixed with 75 % ethanol overnight. After 
centrifugation (Microfuge® 16, Beckman Coulter Life 
Sciences, Taipei, Taiwan) at 664×g for 15 min at 4 °C, the 
resulting supernatants were decanted. Cell pellets were 
stained with 10 µg/mL PI and 10 µg/mL RNase A (Sigma-
Aldrich) in PBS buffer for 30  min at 37  °C in the dark. 
The samples were assayed using a FACScan flow cytom-
eter (Becton–Dickinson, Mansfield, MA, USA) and the 
results were analyzed using FlowJo v7.5.5 software (Tree 
Star Inc., San Carlos, CA).
Assessment of apoptosis
Apoptotic cell death was assessed by annexin V and PI dou-
ble staining (Pharmingen, San Diego, CA, USA) accord-
ing to our previous paper [15]. Briefly, 1 × 106 cells were 
seeded into a 100-mm petri dish and treated with vehicle 
or trans-FA at doses of 0–0.6 mM for 48 h. Next, cells were 
inoculated with 10 µg/mL of annexin V-fluorescein isothio-
cyanate (FITC) and 20 µg/mL of PI and analyzed using a 
FACScan flow cytometer FlowJo v7.5.5 software.
Detection of endogenous ROS
Changes in endogenous ROS levels were assessed using 
the fluorescent indicators 2′,7′-dichlorofluorescin 
diacetate (DCFDA, Sigma-Aldrich) for hydrogen per-
oxide (H2O2) and dihydroethidium (DHE) (Invitrogen) 
for superoxide anion (O2−). A total of 1  ×  105 H1299 
cells were seeded into wells of a 6-well culture plate 
and treated with various concentrations (from 0.03 to 
0.15 mM) of trans-FA for 24 h. Next, cells were harvested 
and stained with 100  nM DCFDA or 1  µM DHE for 
30 min at 37 °C in PBS and then washed twice with PBS. 
Fluorescence was measured by flow cytometry.
Western blot assay
Western blot assays were performed as described previ-
ously [38]. Briefly, cells were harvested and lysed, lysates 
were centrifuged, and protein concentrations of cell pel-
lets were determined. Next, 40  mg quantities of pro-
tein lysate were resolved by 10  % SDS–polyacrylamide 
gel electrophoresis and electro-transferred to polyvi-
nylidene difluoride membranes. The membranes were 
blocked with 5 % nonfat milk and incubated with the fol-
lowing primary antibodies: Thr41/Ser45 phosphorylated 
β-catenin (#2377-S, Epitomics, CA, USA), β-catenin (#sc-
7963, Santa Cruz Biotech., CA, USA), Bax (#ab32503, 
Abcam Inc., Cambridge, MA, USA), survivin (#614701, 
Biolegend, CA, USA), and β-actin (#AM1021b, Abgent, 
San Diego, CA, USA), followed by appropriate second-
ary antibodies (anti-Mouse, #074-1806; anti-Rabbit, 
#074-1506, KPL, Gaithersburg, MD, USA). The Western-
Bright™ ECL kit (Advansta, CA, USA) was used for signal 
detection.
Wound‑healing assay
Quantities of 3 × 105 H1299 cells were seeded in wells of 
a 12-well plate, treated with PBS (as vehicle control) or 
trans-FA (0.03–0.6 mM), and grown to 100 % confluence. 
Culture monolayers were scratched using a pipette tip 
to create a clean 1-mm-wide wound area. After further 
incubation for 16 h, the wound gaps were photographed 
and analyzed using TScratch software (CSE Lab, Zurich, 
Switzerland) [39].
Transwell invasion assay
Invasion assays were performed as described in our 
previous work, with minor modifications [40], using 
8 µm-pore Transwell® chambers (Greiner Bio-One, Fric-
kenhausen, Germany). Control and various concentra-
tions (from 0.03 to 0.6 mM) of trans-FA treated cells were 
cultured in triplicate at 5  ×  104 cells/well in the upper 
inserts of 24-well Transwell® culture plates. Next, cells 
were fixed for 5 min and stained with 0.1 % w/v Giemsa. 
The cells which had invaded the lower inserts were 
counted by arbitrarily selecting five fields from each well. 
The experiments were repeated three times.
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Gelatin zymography
MMP-2 and -9 activity was assessed by gelatin zymog-
raphy as previously described [41], with minor modi-
fication. Briefly, 3 × 105 H1299 cells were seeded into 
wells of 12-well plates and cultured with various con-
centrations of trans-FA for 24  h, after which aliquots 
of culture medium were harvested for gelatin zymog-
raphy analysis. Samples were prepared in standard 
SDS-PAGE loading buffer containing 0.01 % SDS with-
out β-mercaptoethanol and were not boiled before 
use. Next, the samples were subjected to electropho-
resis (150 V for 3 h) on 10 % SDS–polyacrylamide gels 
containing 1  % gelatin. After electrophoresis, the gels 
were thoroughly washed with distilled water contain-
ing 2.5 % Triton X-100 on a gyratory shaker for 30 min 
at room temperature. Gels were incubated in 100  mL 
reaction buffer (40  mM Tris–HCl, pH 8.0; 10  mM 
CaCl2, and 0.02 % NaN3) at 37  °C overnight, followed 
by staining with Coomassie brilliant blue R-250 (Bio 
basic Inc., Markham, Ontario, Canada) and de-stain-
ing with methanol-acetic acid–water (50/75/875, 
v/v/v). The gelatinase activities of MMP-2 and -9 were 
determined by analyzing signal intensity using Gel Pro 
v.4.0 software (Media Cybernetics, Silver Spring, MD, 
USA).
Statistical analysis
All data are mean ± SD from at least three experiments, 
with three replicates per experiment. The significance of 
the differences was analyzed using one-way analysis of 
variance (ANOVA) and SigmaPlot v12.0 software (Systat 
Software Inc., San Jose, CA, USA). P values less than 0.05 
were considered statistically significant.
Results
Radical scavenging activity of trans‑FA
The DPPH assay was used to assess the radical scaveng-
ing activity of trans-FA. Antioxidant activity was calcu-
lated by evaluating the capacity of trans-FA to scavenge 
DPPH. As shown in Fig. 1, trans-FA treatment produced 
significant radical-scavenging activity compared with the 
DMSO control. Vitamin C was serially diluted in metha-
nol (500–7.8 µM) and used in triplicate as a positive con-
trol (Additional file 1).
The short‑term effect of trans‑FA on proliferation of NSCLC 
cells
H1299 cells were treated with PBS (as vehicle control) 
or different concentrations of trans-FA for 24 or 48  h 
before gross morphological changes were examined by 
light microscopy to determine the effect of trans-FA on 
cell growth (Fig. 2a). Cells exhibited no significant change 
in morphology compared with the vehicle control. Next, 
measurement of cell survival was performed by trypan 
blue dye exclusion assay. Low doses (>0.15 mM) of trans-
FA exerted no significant cytotoxic effect, but moderate 
cytotoxicity was observed with 0.3 and 0.6 mM treatment 
for 48 h (Fig. 2b).
The long‑term effect of trans‑FA on colony formation 
and AIG assay in NSCLC cells
As shown in Fig.  3a, trans-FA inhibited colony forma-
tion in H1299 cells after 11 days of treatment. The calcu-
lated colony diameters for trans-FA concentrations of 0, 
0.06, 0.15, 0.3 and 0.6 mM were 100 ± 0.00, 77.19 ± 2.70, 
64.19 ±  2.75, 56.75 ±  4.23 and 4.59 ±  1.25  % (n =  3), 
respectively. Figure  3c shows that long-term treatment 
with trans-FA inhibited the AIG capacity of H1299 cells. 
Furthermore, the results of the colony formation showed 
the selectively inhibitory effect of trans-FA on cellular 
proliferation between lung cancer cells H1299 and lung 
fibroblast cells HEL-299 (Additional file 2). The calculated 
colony diameters for trans-FA at 0, 0.03, 0.06, 0.15, 0.3 
and 0.6 mM were 100 ± 3.10, 95.34 ± 4.18, 85.64 ± 1.08, 
75.51 ± 2.41, 70.41 ± 1.71 and 61.36 ± 2.70 % (n = 3), 
respectively.
Trans‑FA caused moderate G0/G1 accumulation
The effects of 48 h trans-FA treatment on cell cycle pro-
gression in H1299 cells were examined. Trans-FA treat-
ments caused the arrest of the cell cycle at G0/G1 and a 
decrease in the percentage of the G2/M phase (Fig. 4a, b).
Trans‑FA‑induced apoptosis in lung cancer cells
We investigated whether inhibition of proliferation by 
trans-FA was achieved by apoptosis in H1299 cells. 
Only the highest concentration (0.6  mM) of trans-FA 
increased the proportion of Annexin V+/PI+ cells (from 
1.81 to 5.4 %) (Fig. 5). Other concentrations of trans-FA 
used in the study did not induce a significant increase in 
apoptotic populations.
Trans‑FA induced changes in intracellular ROS
The endogenous level of ROS can regulate a variety of 
cellular physiological processes, including survival, 
proliferation, angiogenesis, and signaling pathways 
[42]. Flow cytometry-based detection with DCFDA and 
DHE staining was used to detect endogenous H2O2 and 
O2−, respectively. As shown in Fig. 6, H2O2 concentra-
tions of 100 ± 20, 317 ± 28, 364 ± 23 and 375 ± 20 % 
(n = 3) were observed in H1299 cells treated with dif-
ferent concentrations of trans-FA (0–0.15  mM) for 
24  h. Furthermore, endogenous O2− concentrations 
of 100 ± 9, 100 ± 2, 241 ± 19 and 392 ± 7 % (n = 3) 
were observed with the same trans-FA concentrations 
(Fig. 6b).
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Regulation of survival proteins by trans‑FA
Western blotting was used to examine whether trans-FA 
treatment affected the expression of β-catenin in H1299 
cells. As shown in Fig.  7, trans-FA treatment increased 
β-catenin phosphorylation at Thr41/Ser45 but did not affect 
β-catenin protein levels. The anti-cancer effects of trans-
FA might act by selective inhibition of β-catenin, a tran-
scription factor associated with the growth and migration 
of H1299 cells. Anti-survival Bax protein was increased 
following trans-FA treatment in a dose-responsive man-
ner, although the protein level of survivin was decreased.
Trans‑FA attenuated the motility of lung cancer cells
Wound-healing assays were performed to investigate 
whether trans-FA affected migration of NSCLC cells. 
trans-FA treatment moderately attenuated the migra-
tion of H1299 lung cancer cells (Fig. 8). The area of the 
denuded zone was used as an index of the migratory 
ability of H1299 cells. The areas measured for trans-FA 
concentrations of 0, 0.03, 0.06, 0.15, 0.3 and 0.6  mM 
were 100  %  ±  5.78, 96.86  %  ±  2.69, 98.99  %  ±  4.39, 
93.95  %  ±  6.77, 85.78  %  ±  5.76 and 76.87  %  ±  1.76 
(n = 3), respectively.
Fig. 1 DPPH radical‑scavenging capacity of trans‑FA. a Trans‑FA was tested in an antioxidant assay by measuring the DPPH radical‑scavenging activ‑
ity. The indicated concentrations of trans‑FA were incubated with DPPH respectively as described in the “Methods” section. b Quantificative analysis. 
The radical‑scavenging capacity of trans‑FA at indicated concentrations was quantified as the percentage decrease in absorbance at 492 nm against 
the DMSO control. *P < 0.05 and **P < 0.001, respectively
Fig. 2 Comparison of cell morphology and proliferation between of control and trans‑FA‑treated of NSCLC cells. a H1299 cells were treated with 
PBS as vehicle control or the indicated doses of trans‑FA for 24 and 48 h, respectively. And then, morphology was examined and photographed with 
a light microscope. (phase contrast, X200). b 5 × 104 H1299 cells were seeded onto a 12‑well plate, and cells were treated with indicated doses of 
trans‑FA for 24 and 48 h, respectively. Cell viability was determined using the trypan blue exclusion assay described in “Methods” section. *P < 0.001 
against vehicle control
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Trans‑FA exerted an anti‑invasion effect
A Boyden chamber assay was used to evaluate inva-
sion ability. After treating H1299 cells with various con-
centrations (from 0.03 to 0.6 mM) of trans-FA for 16 h, 
the percentages of invasive cells were 100  %  ±  7.49, 
95.79  %  ±  3.42, 95.61  %  ±  5.86, 88.39  %  ±  7.01, 
82.57 % ± 5.87 and 68.57 % ± 4.48 (n = 3) (Fig. 9).
Trans‑FA reduced the activity of MMP‑2 and MMP‑9
MMP-2 and MMP-9 are gelatinases which degrade 
extracellular matrix and thus regulate the ability of cells 
to migrate. Overexpression of MMP-2 and MMP-9 pro-
motes cancer progression and is highly correlated with 
poor prognosis of cancer patients [43]. Therefore, tar-
geting of MMP-2 and -9 represents a promising strat-
egy for cancer treatment [44]. The activity of MMP-2 
and MMP-9 was determined using a gelatin zymogra-
phy assay (Fig.  10a). Trans-FA treatment (0, 0.03, 0.06, 
0.15, 0.3 and 0.6  mM) significantly reduced the activ-
ity of MMP-2 [100 ±  2.95, 90.59 ±  1.96, 80.43 ±  4.46, 
71.99 ±  2.9, 66.04 ±  1.59 and 55.87 ±  0.26  % (n =  3)] 
(Fig.  10b, c). The activity of MMP-9 [100  ±  4.44, 
105.13 ± 5.29, 94.04 ± 0.99, 112.08 ± 5.24, 78.04 ± 1.86 
and 53.32 ± 2.38 % (n = 3)] was also reduced.
Discussion
The radical scavenger assay findings indicated the potent 
anti-oxidant activity of trans-FA (Fig. 1). Treatment with 
trans-FA for 24 or 48 h did not affect cellular morphol-
ogy and proliferation of lung cancer H1299 cells (Fig. 2). 
However, long-term treatment with trans-FA attenuated 
colony formation and AIG, characteristics of advanced 
cancer, in H1299 cells (Fig. 3). Trans-FA induced moder-
ate cell proliferation at the lowest concentration tested 
(0.03  mM). These results were consistent with previous 
reports that trans-FA promoted proliferation of MCF7 
and BT20 breast cancer cells and neural progenitor cells 
[45, 46]. The colony formation assay also showed the dis-
crepant inhibitory effect of trans-FA on cellular prolifera-
tion of lung cancer cells H1299 and lung fibroblast cells 
Fig. 3 The long‑term effect of trans‑FA on colony formation and anchorage‑independent growth assay of NSCLC. a The assessment of colony 
formation, a 2D indicator of cell proliferation. Adherent H1299 cells were treated with indicated concentrations for 24 h. 5 × 10 cells treated with 
trans‑FA were allowed to form colonies for 11 days. Afterward, colonies were fixed and stained using crystal violet. c Representative results showed 
the formation of tumor spheres, an indicator of 3D for anchorage‑independent growth. H1299 cells were treated with indicated concentrations 
of trans‑FA for 13 days using the soft agar assay. b, d Quantitative analysis of results from a and c showed the number and size of tumorspheres. 
*P < 0.05 and **P < 0.001, respectively
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HEL-299 (Additional file  2), suggesting the potential of 
trans-FA for selectively inhibiting lung cancer. Further-
more, trans-FA significantly inhibited AIG capability in a 
dose-responsive manner.
Trans-FA caused an accumulation of the G0/G1 popu-
lation and induced a moderate increase in the apop-
totic population at the highest concentration (0.6  mM) 
(Fig. 4). G0/G1 cell cycle arrest is usually associated with 
the upregulation of cell cycle regulatory protein p15INK4b 
and p21WAF1/Cip1 [47]. A recent study showed that perillyl 
alcohol, a natural compound purified from citrus fruits 
and herbs, causes G1 arrest and inhibits proliferation of 
human immortalized keratinocyte HaCaT cells through 
inducing p15INK4b and p21WAF1/Cip1 [47]. Annexin V 
staining confirmed that the anti-cancer effects of Trans-
FA were not mediated through apoptosis (Fig. 5).
Excess endogenous ROS may inhibit cellular growth or 
cause cell death [48–51]. The anti-cancer effects of trans-
FA might correlate with increased levels of ROS in H1299 
cells (Fig. 6). ROS content is higher in cancer cells than in 
normal cells, and ROS are reported to be involved in can-
cer cell migration [42]. In this study, trans-FA treatment 
caused the accumulation of both H2O2 and O2−. Trans-
FA (0.03 mM) induced an increase in H2O2, but not O2−. 
Changes in endogenous ROS levels were assessed using 
the fluorescent indicators DCFDA for H2O2 and DHE for 
O2− [52]. Superoxide dismutase (SOD) converts O2− into 
H2O2, and is overexpressed in lung cancer compared with 
Fig. 4 Effect of trans‑FA on cell‑cycle progression of H1299 cells. H1299 cells were treated with the indicated doses, 0.03, 0.06, 0.15, 0.3 and 0.6 mM 
of trans‑FA for 48 h respectively. a An accumulation of G0/G1 population in trans‑FA‑treated H1299 cells and vehicle controls at 48 h. b The quantifi‑
cation analysis. Data are presented as mean ± SD (n = 3). Different letter notations indicate the statistical significance between control and trans‑FA 
treatment groups (a no significance; a vs b and a vs c, statistically significant with P < 0.05 and 0.001, respectively)
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Fig. 5 Effect of trans‑FA on apoptosis of H1299 cells. H1299 cells were treated with indicated doses, 0.03, 0.06, 0.15, 0.3 and 0.6 mM of trans‑FA for 
48 h respectively. Annexin V/PI double staining was performed to detect the apoptosis
Fig. 6 Trans‑FA up‑modulates the endogenous level of ROS in H1299 cells. 1 × 105 H1299 cells were seeded onto a 6‑well plate and treated with 
indicated doses of trans‑FA (from 0.03 to 0.15 mM) 24 h respectively. Afterward, the induction of endogenous ROS was determined by a DCFDA or 
b DHE staining combined with a flow cytometry analysis. **P < 0.001 against vehicle control
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normal and non-malignant lung tissues [53]. Therefore, 
a moderate increase in O2− might be rapidly converted 
into H2O2 in lung cancer cells. However, the signifi-
cant increase in endogenous O2− induced by trans-FA 
(>0.03 mM) may cause saturation of SOD capacity, pre-
venting further conversion of O2− to H2O2. Accordingly, 
increased levels of H2O2 might be the product of O2− 
conversion by SOD in H1299 cells following low dose 
(0.03 mM) trans-FA treatment.
β-catenin is a transcription factor involved in cell 
growth and cell migration pathways. Wnt/β-catenin 
signaling is thus essential for the maintenance of neu-
ronal progenitor proliferation [54]. However, phos-
phorylated β-catenin is inactivated and undergoes 
proteasomal degradation, causing the inhibition of cell 
growth [55].
With respect to tumorigenesis, constitutive activation 
or overexpression of β-catenin is frequently observed in 
cancers, including rectal cancer [56], colon cancer [57], 
breast cancer [58], prostate cancer [59], glioma [60], 
and lung cancer [61]. Furthermore, overexpression of 
Fig. 7 Effect of trans‑FA on survival protein of H1299 cells. H1299 
cells were treated with the indicated doses, 0.03, 0.06, 0.15, 0.3 and 
0.6 mM of trans‑FA for 48 h. Western blot assay was performed
Fig. 8 Effect of trans‑FA on the migration of H1299 cells. Trans‑FA inhibits cell migration of NSCLC tumor H1299 cells at the highest dose (0.6 mM).  
a 3 × 105 cells were seeded in a 12‑well plate and cells were scraped to create a clean 1‑mm area within the confluent culture. Cells were treated 
with the indicated doses of 0.03, 0.06, 0.15, 0.3 and 0.6 mM of trans‑FA for 16 h. Afterward, the wound gaps were photographed using an inverted 
phase‑contrast microscopy. b The quantification analysis. *P < 0.05 for trans‑FA treatments against vehicle control
Fig. 9 Effect of trans‑FA on the invasion of H1299 cells. a Cells were treated with the indicated doses of 0.03, 0.06, 0.15, 0.3 and 0.6 mM of trans‑FA 
for 16 h and stained with 0.1 % w/v Giemsa stain respectively. b The results of the quantificative analysis. *P < 0.05 and **P < 0.001 for trans‑FA treat‑
ments against vehicle control, respectively
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β-catenin enhances the expression of cyclin D1, a critical 
factor for G1/S transition during cell cycle progression in 
colon carcinoma cells [62]. S-adenosylmethionine and 
its metabolite, methylthioadenosine, inhibited β-catenin 
signaling by multiple mechanisms in colon cancer, and 
thus might have the potential to prevent tumorigenesis 
[63]. Furthermore, Wnt/β-catenin signaling was shown 
to be a potent activator of ROS generation, resulting in 
DNA damage and acceleration of cellular senescence 
[64]. Furthermore, Wnt/β-catenin signaling potently 
activated ROS generation in mesenchymal stem cells 
[64–66].
To clarify the underlying mechanism of trans-FA-
induced anti-lung cancer activities, we examined 
whether trans-FA could affect the expression of cell pro-
liferation-related transcription factor β-catenin using 
western blotting (Fig.  7). Our results demonstrated 
that trans-FA treatment promoted the phosphorylation 
of β-catenin at residues Thr41 and Ser45 [55] and led to 
the proteasomal degradation of cytoplasmic β-catenin, 
causing the downregulation of β-catenin protein lev-
els. The Wnt pathway regulated MMP-2/-9 expression 
by directly targeting the MMP promoter through T-cell 
factor (TCF), a β-catenin interacting partner, therefore 
promoting cellular migration [67]. In effector T cells, 
endothelial cell-derived Wnt induced the expression of 
MMP-2/-9 through activating the Frizzled receptors to 
regulate the transmigration of T cells. In contrast, Wnt 
signaling blockade reduced the migration of effector T 
cells in vitro [67].
In addition to β-catenin, we also examined the role 
of pro-survival protein Bax, a key anti-survival factor, 
can promote apoptosis by binding to and antagoniz-
ing pro-survival Bcl-2 proteins such as Bcl-2 or Bcl-xL 
[68]. Conversely, survivin is a member of the inhibitor 
of apoptosis (IAP) family and acts as an inhibitor of 
Fig. 10 Effect of trans‑FA on activities of MMP‑2 and MMP‑9. H1299 cells were treated with indicated concentrations of trans‑FA for 24 h respec‑
tively. a The activities of MMP‑2 and MMP‑9 were determined by a gelatin zymography assay (n = 3). b, c The results of the quantificative analysis.  
b *P < 0.05 and **P < 0.001 for trans‑FA treatments against vehicle respectively. c *P < 0.001 for trans‑FA treatments against vehicle control
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caspase activation, thereby negatively regulating apopto-
sis or programmed cell death [69]. Both the Bcl-2 family 
and IAP proteins are critical regulators of cell prolifera-
tion and survival. In our study, the significant changes 
in Bax and survivin expression occurred alongside the 
anti-proliferation effects observed following trans-FA 
treatment (Fig. 7). As shown using colony formation and 
AIG assays, trans-FA treatment might impair cell prolif-
eration of H1299 cells. Apart from in cells treated with 
higher concentrations (0.3 and 0.6  mM) of trans-FA, 
no significant increase in the population of apoptotic 
cells was detected. Survivin is considered an apoptosis 
inhibitor which promotes cellular proliferation, although 
decreased expression of survivin may not always cause 
apoptosis [69]. Ito et al. showed that both human hepa-
tocellular carcinoma (HCC) cell lines and patient tissues 
expressed high levels of survivin mRNA, with detectable 
levels not found in normal and non-tumor areas of liver 
[70]. Survivin expression may be an indicator of cellular 
proliferation but not apoptosis in HCC tissues [70]. The 
degradation or expression Bax may represent a thresh-
old for inducing apoptosis [71]. These results might 
explain how trans-FA treatment caused an increase in 
Bax protein expression but did not significantly induce 
apoptosis in H1299 cells at most concentrations tested 
(0.015–0.15 mM). These observations suggest that trans-
FA treatment attenuates cellular proliferation rather 
than cellular survival. Therefore, the results of the pro-
liferation assay imply that the anti-migratory effect of 
trans-FA may also be mediated by regulating the balance 
of pro-survival and anti-survival proteins in lung cancer 
cells.
Extracellular matrix-degrading MMPs, especially 
MMP-2 and MMP-9, are involved in the metastasis 
of cancer cells [72]. Trans-FA treatment inhibited the 
migration and invasion of lung cancer cells and con-
currently attenuated the activities of both MMP-2 and 
MMP-9 (Figs.  8, 9, 10). These observations suggest a 
positive correlation between MMP activity and trans-FA-
induced anti-migration in lung cancer cells.
Based on these observations, we propose that the 
anti-lung cancer effects of trans-FA might act through 
the modulation of endogenous ROS and β-catenin sta-
bilization. Trans-FA induced the production of endog-
enous ROS and may cause β-catenin phosphorylation, 
resulting in proteasomal degradation. In addition, 
trans-FA regulated the balance between pro-survival 
and pro-apoptosis signals and downregulated the 
activities of metastasis-associated MMP-2 and MMP-9 
(Fig. 11).
Conclusion
Various concentrations (0.06–0.6 mM) of trans-FA exert 
both anti-proliferation and anti-migration effects in the 
human lung cancer cell line H1299.
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